Literature DB >> 32907486

Exercise Regulates MicroRNAs to Preserve Coronary and Cardiac Function in the Diabetic Heart.

Rajesh Katare1, Daryl O Schwenke1, Jason Kar-Sheng Lew1, James T Pearson2,3, Eugene Saw1, Hirotsugu Tsuchimochi2, Melanie Wei1, Nilanjan Ghosh1, Cheng-Kun Du2, Dong-Yun Zhan2, Meihua Jin4, Keiji Umetani5, Mikiyasu Shirai4.   

Abstract

RATIONALE: Diabetic heart disease (DHD) is a debilitating manifestation of type 2 diabetes mellitus. Exercise has been proposed as a potential therapy for DHD, although the effectiveness of exercise in preventing or reversing the progression of DHD remains controversial. Cardiac function is critically dependent on the preservation of coronary vascular function.
OBJECTIVE: We aimed to elucidate the effectiveness and mechanisms by which exercise facilitates coronary and cardiac-protection during the onset and progression of DHD. METHODS AND
RESULTS: Diabetic db/db and nondiabetic mice, with or without underlying cardiac dysfunction (16 and 8 weeks old, respectively) were subjected to either moderate-intensity exercise or high-intensity exercise for 8 weeks. Subsequently, synchrotron microangiography, immunohistochemistry, Western blot, and real-time polymerase chain reaction were used to assess time-dependent changes in cardiac and coronary structure and function associated with diabetes mellitus and exercise and determine whether these changes reflect the observed changes in cardiac-enriched and vascular-enriched microRNAs (miRNAs). We show that, if exercise is initiated from 8 weeks of age, both moderate-intensity exercise and high-intensity exercise prevented the onset of coronary and cardiac dysfunction, apoptosis, fibrosis, microvascular rarefaction, and disruption of miRNA signaling, as seen in the nonexercised diabetic mice. Conversely, the cardiovascular benefits of moderate-intensity exercise were absent if the exercise was initiated after the diabetic mice had already established cardiac dysfunction (ie, from 16 weeks of age). The experimental silencing or upregulation of miRNA-126 activity suggests the mechanism underpinning the cardiovascular benefits of exercise were mediated, at least in part, through tissue-specific miRNAs.
CONCLUSIONS: Our findings provide the first experimental evidence for the critical importance of early exercise intervention in ameliorating the onset and progression of DHD. Our results also suggest that the beneficial effects of exercise are mediated through the normalization of cardiovascular-enriched miRNAs, which are dysregulated in DHD.

Entities:  

Keywords:  angiography; diabetes mellitus; exercise; heart disease; microRNAs

Mesh:

Substances:

Year:  2020        PMID: 32907486     DOI: 10.1161/CIRCRESAHA.120.317604

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  12 in total

1.  Exercise Training in Diabetes: Start Earlier or Exercise Harder.

Authors:  Haobo Li; Margaret H Hastings; Anthony Rosenzweig
Journal:  Circ Res       Date:  2020-11-05       Impact factor: 17.367

2.  Diabetes induces dysregulation of microRNAs associated with survival, proliferation and self-renewal in cardiac progenitor cells.

Authors:  Nima Purvis; Sweta Kumari; Dhananjie Chandrasekera; Jayanthi Bellae Papannarao; Sophie Gandhi; Isabelle van Hout; Sean Coffey; Richard Bunton; Ramanen Sugunesegran; Dominic Parry; Philip Davis; Michael J A Williams; Andrew Bahn; Rajesh Katare
Journal:  Diabetologia       Date:  2021-03-02       Impact factor: 10.122

3.  Predictive value of miRNA-126 on in-stent restenosis in patients with coronary heart disease: A protocol for meta-analysis and bioinformatics analysis.

Authors:  Xianke Qiu; Jun Wang; Zhongping Shi; Xiaojun Ji; Yiwei Huang; Haiyue Dai
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

Review 4.  Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy.

Authors:  Amit K Rai; Brooke Lee; Ramesh Gomez; Deepu Rajendran; Mahmood Khan; Venkata Naga Srikanth Garikipati
Journal:  Front Physiol       Date:  2021-01-22       Impact factor: 4.566

5.  Bioinformatics Analysis of the MicroRNA-Metabolic Gene Regulatory Network in Neuropathic Pain and Prediction of Corresponding Potential Therapeutics.

Authors:  Huai-Gen Zhang; Li Liu; Zhi-Ping Song; Da-Ying Zhang
Journal:  J Mol Neurosci       Date:  2021-09-27       Impact factor: 2.866

6.  Upregulated miR-200c is associated with downregulation of the functional receptor for severe acute respiratory syndrome coronavirus 2 ACE2 in individuals with obesity.

Authors:  Jayanthi Bellae Papannarao; Daryl O Schwenke; Patrick Manning; Rajesh Katare
Journal:  Int J Obes (Lond)       Date:  2021-10-08       Impact factor: 5.095

7.  Therapeutic knockdown of miR-320 improves deteriorated cardiac function in a pre-clinical model of non-ischemic diabetic heart disease.

Authors:  Nilanjan Ghosh; Sonya Fenton; Isabelle van Hout; Gregory T Jones; Sean Coffey; Michael J A Williams; Ramanen Sugunesegran; Dominic Parry; Philip Davis; Daryl O Schwenke; Anirudha Chatterjee; Rajesh Katare
Journal:  Mol Ther Nucleic Acids       Date:  2022-07-13       Impact factor: 10.183

Review 8.  Non-coding RNAs: Important participants in cardiac fibrosis.

Authors:  Yiheng Dong; Naling Peng; Lini Dong; Shengyu Tan; Xiangyu Zhang
Journal:  Front Cardiovasc Med       Date:  2022-07-28

Review 9.  Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities.

Authors:  Izabela Tuleta; Nikolaos G Frangogiannis
Journal:  Adv Drug Deliv Rev       Date:  2021-07-29       Impact factor: 17.873

10.  Activation of the cardiac non-neuronal cholinergic system prevents the development of diabetes-associated cardiovascular complications.

Authors:  Yoshihiko Kakinuma; Martin Fronius; Rajesh Katare; Eng Leng Saw; James T Pearson; Daryl O Schwenke; Pujika Emani Munasinghe; Hirotsugu Tsuchimochi; Shruti Rawal; Sean Coffey; Philip Davis; Richard Bunton; Isabelle Van Hout; Yuko Kai; Michael J A Williams
Journal:  Cardiovasc Diabetol       Date:  2021-02-22       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.